14-day Premium Trial Subscription Try For FreeTry Free
Currently predicting for Tue, 7 May 2024

Trading levels for PBYI

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 5.14 11.33 %
R2 4.94 6.99 %
R1 4.82 4.30 %
Current price: 4.62
Support S1 4.42 -4.38 %
S2 4.29 -7.06 %
S3 4.09 -11.40 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 5.35 15.80 %
R2 5.33 15.37 %
R1 4.66 0.87 %
Current price 4.62
Support S1 4.30 -6.93%
S2 0 .
S3 0 .

PBYI Predictions History

4 years ago
Ioan136562 predicted that PBYI for 2020-01-29 is going

Rank:

4 years ago
machinecode1000101 predicted that PBYI for 2020-01-29 is going $8.10 (-2.82%)

Rank:

4 years ago
QoqananiMpala133224 predicted that PBYI for 2020-01-29 is going $9.05 (8.58%)

Rank:

5 years ago
NameNotImportant predicted that PBYI for 2019-05-06 is going $31.50 (-1.38%)

5 years ago
NameNotImportant predicted that PBYI for 2019-04-29 is going $32.92 (-1.47%)

5 years ago
JS predicted that PBYI for 2019-03-27 is going $39.49 (3.27%)

5 years ago
PumpTheseNumbers predicted that PBYI for 2019-03-27 is going $40.33 (5.47%)

5 years ago
JS predicted that PBYI for 2019-03-06 is going $37.22 (1.53%)

5 years ago
Gp predicted that PBYI for 2019-03-06 is going $42.07 (14.76%)

5 years ago
PumpTheseNumbers predicted that PBYI for 2019-03-06 is going $38.93 (0.80%)

Click to get the best stock tips daily for free!

About Puma Biotechnology Inc

Puma Biotechnology Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advance... PBYI Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT